ReviewCurrent radiopharmaceuticals2020
Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications.
Review in Current radiopharmaceuticals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Pooled it
- Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics.Journal of advanced research · 2026Review
- A comparative assessment of radiochemical purity and yield of [EJNMMI radiopharmacy and chemistry · 2026Article
- PSMA-targeted fluorescent probe for NIR-II imaging in prostate cancer intraoperative navigation and tumor margin mapping.Theranostics · 2026Article
- Raman spectroscopic modality to examine therapeutic efficacy of Galectin-3 inhibitor in prostate cancer.Biochemical and biophysical research communications · 2025Article
- PSMA-Targeting Imprinted Nanogels for Prostate Tumor Localization and Imaging.Advanced healthcare materials · 2025Article
- Therapeutic response and safety of radioligand therapy withMedical oncology (Northwood, London, England) · 2024Article
- Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.Advanced healthcare materials · 2024Article
- Use of PSMA PET/CT to detect prostate cancer metastatic to a preexisting thyroid nodule.NPJ precision oncology · 2024Article
- Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled withACS pharmacology & translational science · 2024Article
- Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology.Frontiers in immunology · 2024Review
- Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties.Molecular imaging and biology · 2023Article
- The Application of Radiolabeled Targeted Molecular Probes for the Diagnosis and Treatment of Prostate Cancer.Korean journal of radiology · 2023Review
- Oldie but Goodie: Is Technetium-99m Still a Treasure Trove of Innovation for Medicine? A Patents Analysis (2000-2022).Journal of medicinal chemistry · 2023Review
- Targeting Carbohydrate Mimetics of Tetrahydrofuran-Containing Acetogenins to Prostate Cancer.Molecules (Basel, Switzerland) · 2023Article
- PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Pharmacological Optimization of PSMA-Based Radioligand Therapy.Biomedicines · 2022Review
- The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer-A Practical Clinical Review.Cancers · 2022Review
- Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.Signal transduction and targeted therapy · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rising incidence rate of prostate cancer (PCa) has promoted the development of new diagnostic and therapeutic radiopharmaceuticals during the last decades. Promising improvements have been achieved in clinical practice using prostate specific membrane antigen (PSMA) labeled agents, including specific antibodies and small molecular weight inhibitors. Focusing on molecular docking studies, this review aims to highlight the progress in the design of PSMA targeted agents for a potential use in nuclear medicine.
resultsAlthough the first development of radiopharmaceuticals able to specifically recognize PSMA was exclusively oriented to macromolecule protein structure such as radiolabeled monoclonal antibodies and derivatives, the isolation of the crystal structure of PSMA served as the trigger for the synthesis and the further evaluation of a variety of low molecular weight inhibitors. Among the nuclear imaging probes and radiotherapeutics that have been developed and tested till today, labeled Glutamate-ureido inhibitors are the most prevalent PSMA-targeting agents for nuclear medicine applications.
conclusionPSMA represents for researchers the most attractive target for the detection and treatment of patients affected by PCa using nuclear medicine modalities. [99mTc]MIP-1404 is considered the tracer of choice for SPECT imaging and [68Ga]PSMA-11 is the leading diagnostic for PET imaging by general consensus. [18F]DCFPyL and [18F]PSMA-1007 are clearly the emerging PET PSMA candidates for their great potential for a widespread commercial distribution. After paving the way with new imaging tools, academic and industrial R&Ds are now focusing on the development of PSMA inhibitors labeled with alpha or beta minus emitters for a theragnostic application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.